Navigation Links
Upcoming meeting will explore new technologies for glaucoma clinical drug trials
Date:2/13/2008

Rockville, MD The National Eye Institute (NEI) and the Food and Drug Administration (FDA) are sponsoring a symposium to consider new disease-relevant outcome measures appropriate for evaluating glaucoma therapies.

Currently, clinical drug trials for glaucoma therapies rely on standard perimetric criteria i.e., a vision field test as the primary functional outcome measure.

However, new technologies that assess abnormalities and changes in the optic nerve structure and its function offer vision researchers alternative pathways to better diagnose and treat glaucoma.

This symposium will focus on new outcome measures appropriate for evaluation of glaucoma therapies. The aim is to encourage the development of new glaucoma therapies, facilitate their evaluation and ultimately benefit patients.

Attendees will include:

  • Clinical researchers/basic scientists
  • Clinical trialists
  • Pharmaceutical company representatives
  • Legal/advocacy firms
  • Associations
  • Biotech companies

Registrants will be able to submit questions/comments in advance through a link on their registration confirmation notice.

Glaucoma facts

Glaucoma a potentially blinding but treatable group of diseases affects 2.2 million Americans age 40 and older, resulting in direct medical costs of $2.86 billion annually.

  • Glaucoma robs individuals of peripheral and eventually central vision.
  • Glaucoma is a complex group of neurodegenerative diseases that arises from progressive damage to the optic nerve and retinal ganglion cells and their axons.
  • It is one of the four major aging eye diseases, alongside age-related macular degeneration, diabetic retinopathy and cataracts.
  • About 50 percent of sufferers are unaware they have the disease.
  • Glaucoma disproportionately affects minority populations: It is three times more common in African Americans than in whites and is the leading cause of irreversible vision loss in African Americans and Hispanics.
  • There is a large public health burden from glaucoma due to decreased productivity, reduced independence and diminished quality of life.


'/>"/>

Contact: Lancey Cowan
lcowan@arvo.org
Association for Research in Vision and Ophthalmology
Source:Eurekalert

Related medicine news :

1. Amscot Financial Contributes to the Juvenile Diabetes Research Foundation, Supporting Upcoming Walk for a Cure
2. Align Technology Executives to Present at Upcoming Financial Conferences
3. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
4. The Advisory Board Company to Present at Upcoming Conferences
5. Coherent Announces Director Slate for Upcoming Annual Meeting
6. Poniard Pharmaceuticals Announces Upcoming Conference Participation
7. LCA-Vision Announces Upcoming Investment Community Events
8. WellPoint Announces Appearance at Upcoming Conference
9. Thought Leaders in Morbid Obesity Treatment Convene at Upcoming Surgical Conference
10. GSI to Present at Upcoming Investor Growth Conferences
11. WebMD to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
Breaking Medicine Technology: